AEON Biopharma (NASDAQ: AEON) CMO granted RSUs and modifies 1,316,872-unit award

Rhea-AI Filing Summary

AEON Biopharma, Inc. chief medical officer Chad Oh reported receiving equity awards of Class A common stock as compensation. On February 17, 2026, he was granted 862,500 restricted stock units that vest in four substantially equal annual installments, starting on the first anniversary of the grant date, subject to continued service.

On March 4, 2026, 1,316,872 previously cash-settled restricted stock units granted on May 21, 2025 were modified to be settled in stock instead of cash upon vesting, while keeping the same four-year vesting schedule from the 2025 grant date. After these awards, his direct holdings increased to 2,183,436 shares of Class A common stock. These are compensation-related acquisitions, not open-market purchases or sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oh Chad

(Last) (First) (Middle)

C/O AEON BIOPHARMA, INC.

5 PARK PLAZA, SUITE 1750

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	02/17/2026		A		862,500	A	$0(1)	866,564	D
Class A Common Stock(2)	03/04/2026		A		1,316,872	A	$0(2)	2,183,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

2. Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.

	/s/ Alexander Wilson, as Attorney-in-Fact, for Chad Oh	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AEON (AEON) report for its chief medical officer?

AEON Biopharma’s chief medical officer Chad Oh reported receiving equity awards, not open-market trades. He was granted 862,500 restricted stock units and had 1,316,872 cash-settled units modified to stock-settled, all vesting in four annual installments, increasing direct holdings to 2,183,436 shares.

How many AEON Biopharma (AEON) shares does Chad Oh hold after these awards?

Following the reported equity awards, Chad Oh directly holds 2,183,436 shares of AEON Biopharma Class A common stock. This total reflects both the new 862,500-unit grant and the 1,316,872 restricted stock units modified from cash-settled to stock-settled upon vesting.

Were Chad Oh’s recent AEON (AEON) Form 4 transactions open-market buys or sells?

The reported transactions were not open-market buys or sells. They were equity compensation events: a grant of 862,500 restricted stock units and a modification of 1,316,872 previously cash-settled units to be settled in stock when they vest, subject to continued service.

What are the vesting terms of Chad Oh’s new AEON Biopharma restricted stock units?

The 862,500 restricted stock units granted on February 17, 2026 vest in substantially equal installments over four years. Vesting occurs on each of the first, second, third, and fourth anniversaries of the grant date, contingent on continued service through each vesting date.

What change was made to AEON (AEON) restricted stock units granted in May 2025?

Restricted stock units granted on May 21, 2025, totaling 1,316,872 units, were modified on March 4, 2026. They will now be settled in AEON stock instead of cash upon vesting, while keeping their original four-year, annually vesting schedule and continued-service requirement.